Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab vs EPd in Relapsed/Refractory Multiple Myeloma
NCT05730036Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2023
- Primary completion
- Apr 2033
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of linvoseltamab in multiple myeloma (MM), sponsored by Regeneron Pharmaceuticals. Started Sep 2023; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05730036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05730036.